Medacta Group Future Growth

Future criteria checks 3/6

Medacta Group is forecast to grow earnings and revenue by 18.8% and 12% per annum respectively. EPS is expected to grow by 21.8% per annum. Return on equity is forecast to be 20% in 3 years.

Key information

18.8%

Earnings growth rate

21.8%

EPS growth rate

Medical Equipment earnings growth	22.9%
Revenue growth rate	12.0%
Future return on equity	20.0%
Analyst coverage	Good
Last updated	26 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0A05 - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	744	99	48	150	7
12/31/2025	664	84	38	146	7
12/31/2024	579	75	24	123	2
6/30/2024	544	56	-14	80	N/A
3/31/2024	528	52	-10	77	N/A
12/31/2023	511	47	-6	75	N/A
9/30/2023	496	49	2	78	N/A
6/30/2023	481	50	9	80	N/A
3/31/2023	459	48	8	77	N/A
12/31/2022	437	46	7	74	N/A
9/30/2022	417	47	4	72	N/A
6/30/2022	397	47	2	70	N/A
3/31/2022	380	49	1	62	N/A
12/31/2021	363	52	-1	54	N/A
9/30/2021	354	54	11	58	N/A
6/30/2021	345	57	22	63	N/A
3/31/2021	324	47	22	61	N/A
12/31/2020	302	37	22	60	N/A
9/30/2020	298	24	9	50	N/A
6/30/2020	294	10	-5	40	N/A
3/31/2020	302	11	-7	41	N/A
12/31/2019	311	12	-9	43	N/A
9/30/2019	301	22	-3	46	N/A
6/30/2019	291	33	3	50	N/A
3/31/2019	282	39	7	58	N/A
12/31/2018	273	46	11	66	N/A
12/31/2017	245	33	N/A	52	N/A
12/31/2016	219	39	N/A	56	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0A05's forecast earnings growth (18.8% per year) is above the savings rate (1.9%).

Earnings vs Market: 0A05's earnings (18.8% per year) are forecast to grow faster than the UK market (14.4% per year).

High Growth Earnings: 0A05's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0A05's revenue (12% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: 0A05's revenue (12% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0A05's Return on Equity is forecast to be low in 3 years time (20%).

Medacta Group Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

Medacta Group SA Provides Revenue Guidance for the Year 2022

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Recent updates

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Now 21% undervalued after recent price drop

Dividend of CHF0.55 announced

Full year 2023 earnings released: EPS: €2.37 (vs €2.32 in FY 2022)

Insufficient new directors

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Upcoming dividend of CHF0.54 per share at 0.5% yield

Full year 2022 earnings released: EPS: €2.32 (vs €2.58 in FY 2021)

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

Medacta Group SA Provides Revenue Guidance for the Year 2022

Medacta Group SA Approves Distribution

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Investor sentiment improved over the past week

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Medacta Announces First U.S. Surgery with the New M.U.S.T. Lt System in Minimally Invasive Spine Surgery

Full year 2020 earnings released: EPS €1.86 (vs €0.59 in FY 2019)

Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem

Medacta Adds the MyHip Planner and the MyHip Verifier Tools to Its Medicine Solutions for Hip Replacement

Medacta Group SA to Report Q2, 2021 Final Results on Sep 10, 2021

Medacta Group SA, Annual General Meeting, May 25, 2021

Medacta Announces Successful Completion of the First TKA Surgery in the U.S. with NextAR Augmented Reality-Based Surgical Platform

Medacta Expands Its Knee Offerings with New SensiTiN System with Low Metal Ion Release

First half earnings released

Medacta Group SA to Report Fiscal Year 2020 Results on Jan 21, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies